About Taiwan Liposome Company
Taiwan Liposome Company (TLC) is a biopharmaceutical company engaging in research, development and commercialization of proprietary drug delivery system for improving the treatment of cancer, ophthalmic conditions, and infectious diseases.
Taiwan Liposome Company Patents
Taiwan Liposome Company has filed 39 patents.
Drug delivery devices, Dosage forms, Local anesthetics, General anesthetics, Anesthesia
Drug delivery devices, Dosage forms, Local anesthetics, General anesthetics, Anesthesia
Latest Taiwan Liposome Company News
Feb 1, 2023
Major Players Graybug Vision Inc., URSAPHARM Arzneimittel GmbH, Allergan Plc., Alimera Sciences, Ocular Therapeutix, Inc., Taiwan Liposome Company Ltd., pSivida,, Santen Pharmaceutical Co., Ltd, Eyegate Pharma, Envisia Therapeutics, Vision Ophthalmology Group GmbH, Valeant Pharmaceuticals International, Inc, Clearside Biomedical among others Segmentation Analysis Nano-particle drug delivery systems are expected to be the fastest-growing segment in 2022. The technology segment is nano-particle drug delivery systems, implantable ocular drug delivery systems, and particulate drug delivery systems. The nano-particle drug delivery systems segment is expected to witness the highest growth rate during the forecast period. The use of nanoparticles has been developed as an alternative to typical eye drops for overcoming obstacles, improving drug penetration, and extending drug levels by a few internal doses of medication administration. In addition, new products with altered formulations are predicted to meet market demands. Solution is expected to be the fastest-growing segment in 2022. The dosage form segment includes suspension, gels, solution, emulsion, and ointments. The solution segment is expected to witness the highest growth rate during the forecast period. In addition to treating itchy or tired eyes related to allergies, eye drops can also be prescribed to treat viral or bacterial infections, as well as glaucoma. A growing market for eye drops is influenced by the growing availability of OTC eye drops, patient compliance issues, and eye illnesses. Prescription drugs are expected to be the fastest-growing segment in 2022. The product type segment is OTC Drugs and prescription drugs. The pescription drugs segment is expected to witness the highest growth rate during the forecast period. The growth of the prescription drug industry is due to the rise in diseases including AMD and diabetic retinopathy. Two further factors that could boost demand in the prescription industry are enhanced safety and efficacy. Some of the drugs available in this market are Lotemax gel/ointment, Zylet, Durezol, Bepreve (bepotastine besilate ophthalmic solution), and prescription artificial tears. Bepreve is an antihistamine used to treat allergic conjunctivitis. The lubricating and moisturising components in several medicinal drugs temporarily boost the production of tears. Because they are believed to be the most effective at treating eye disorders, prescription medications are preferred to over-the-counter ones. Anti-VEGF agents are expected to be the fastest-growing segment in 2022. The drug class segment is anti-glaucoma, antiallergy, anti-VEGF agents, and anti-inflammatory. The anti-VEGF agents segment is expected to witness the highest growth rate during the forecast period. The market for eye drops is expected to develop as a result of the rising OTC availability of eye drops, patient compliance concerns, and the prevalence of eye diseases. Additionally, it is anticipated that rising anti-VEGF agent demand and usage, as well as the existence of significant market players with broad product portfolios, would all contribute to the segment's expansion. For instance, LUCENTIS, a prescription medication from Genentech USA, is used to treat people with myopic choroidal neovascularization, AMD, and diabetic retinopathy. Another element influencing the expansion of the segment is how successfully market leaders like Avastin, LUCENTIS, and others performed. Regional Analysis The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the ocular drug delivery market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North American region witnessed a major share. Several factors contribute to North America's leading position in the global ocular drug delivery market, such as product awareness, the prevalence of eye diseases, and the presence of major players. Additionally, the aging population in the US will likely increase the incidence of eye diseases, which will in turn drive the adoption of ocular drug delivery products. Country Analysis Germany Germany's ocular drug delivery market size was valued at USD 1.14 billion in 2022 and is expected to reach USD 1.9 billion by 2030, at a CAGR of 6.8% from 2023 to 2030. Germany is Europe's second largest market, and some of the top players want to expand there. It is challenging to get drug approvals in Germany because of the country's stringent regulations. China China’s ocular drug delivery market size was valued at USD 1.17 billion in 2022 and is expected to reach USD 2.01 billion by 2030, at a CAGR of 7% from 2023 to 2030. Among the country's residents, there are also the largest numbers of those with poor vision that haven't yet been corrected, and this number is predicted to increase in the near future. During the forecast period, the market for ocular drug delivery is expected to grow due to the country's large number of ophthalmologists. India India's ocular drug delivery market size was valued at USD 0.9 billion in 2022 and is expected to reach USD 1.5 billion by 2030, at a CAGR of 6.9% from 2023 to 2030. As a result of changing eating patterns and genetic influences, as well as increased awareness campaigns for eye care and treatment, there is a growing elderly population, an increase in diabetic patients. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of this market is mainly driven owing to the rising number of untreated poor vision patients globally. Buy Now Full Report @ https://greyviews.com/checkout/510/single_user_license Contact Us Medical Power Supply Devices Market Size By Manufacturing Type (CF Rating, Customized and Standard), By Convertor Type (DC-DC Power Supply and AC-DC Power Supply), By End-User (Home Care Setting, Clinics, Ambulatory Surgical Centers, Rehabilitation Centers, Diagnostics Centers, Hospitals, and Others), Regions, Segmentation, and Projection till 2030 Medical Disposables Market Size By Product (Drug Delivery Products, Respiratory Supplies, Disposable Gloves, Disposable Masks, Disposable Eye Gear, Hand Sanitizers, Wound Management Products, Incontinence Products, Dialysis Disposables, Diagnostic & Laboratory Disposables, Sterlization Supplies, Non-Woven Disposables, and Others), By Raw Material (Nonwoven Material, Plastic Resin, Paper & Paperboard, Glass, Metals, Rubber, and Others), By End-User (Outpatient/Primary Care Facilities, Home Healthcare, Hospitals, and Others), Regions, Segmentation, and Projection till 2030
Taiwan Liposome Company Frequently Asked Questions (FAQ)
When was Taiwan Liposome Company founded?
Taiwan Liposome Company was founded in 1997.
Where is Taiwan Liposome Company's headquarters?
Taiwan Liposome Company's headquarters is located at 601 Gateway Boulevard, South San Francisco.
What is Taiwan Liposome Company's latest funding round?
Taiwan Liposome Company's latest funding round is IPO.
Who are the investors of Taiwan Liposome Company?
Investors of Taiwan Liposome Company include YFY Group, TaiAn Technologies, Boston Life Science Venture Corp and Burrill & Company.
Who are Taiwan Liposome Company's competitors?
Competitors of Taiwan Liposome Company include Erydel, Mirus Bio, EZRA Innovations, Quinnova Pharmaceuticals, MediQuest Therapeutics and 7 more.
Compare Taiwan Liposome Company to Competitors
BioMed Vision Technologies LC (BMVT) has a particular interest in the development of veterinary medical equipment for diagnosing ocular diseases and systems for drug delivery such as programmable pumps for ocular medications delivery in horses and dogs. BMVT is also in the process of developing software applications for electronic management of medical records.
EZRA Innovations currently holds exclusive worldwide rights in a controlled-release drug delivery system. Drug Surfactant Complex (DSC) Deoxycholate is used in combination with active pharmaceutical ingredients (API), DSC possesses the ability to change the chemical moiety of existing drugs and better extend release rates.
Next Breath is a contract services provider that focuses on the pharmaceutical, biotech, and medical device industries. The company offers a range of in-vitro services, including pre-clinical formulation development and analytical testing, to support submissions to regulatory agencies. Its primary customers are innovators of promising drug molecules and inventors of pulmonary and nasal drug delivery devices. It is based in Baltimore, Maryland.
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
utilized "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds.ï¿½MACUGEN, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.
GelMed Sciences, Inc. is commercializing three new agriculture product inventions initially developed by the Penn State University Research Foundation (PSRF). The company's offerings include a Poultry Feed Withdrawal Supplement (PFWS), a Livestock Genetic Marker, and a Gel Drug Delivery Systems which all aim to improve quality and/or output of agricultural products.